Kevin Marks Email

President & CEO . Delphia Therapeutics

Current Roles

Employees:
29
Revenue:
$5.4M
About
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.
Delphia Therapeutics Address

Cambridge, MA
United States
Delphia Therapeutics Email